Adjuvants and malaria vaccine development

Chemical Immunology

Volumn 80, Issue , 2002, Pages 343-365

  Xiao, Lihua ^a   Rafi Janajreh, Asimah ^a   Patterson, Pamela ^a   Zhou, Zhiyong ^a   Lal, Altaf A ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM POTASSIUM SULFATE; COPOLYMER; FREUND ADJUVANT; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 12; INTERLEUKIN 2; MALARIA VACCINE; MONTANIDE ISA 720; N ACETYLMURAMYLALANYL DEXTRO ISOGLUTAMINYLALANYL DIPALMITOYLPHOSPHATIDYLETHANOLAMINE; QS 21; UNCLASSIFIED DRUG;

ANTIBODY TITER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CPG ISLAND; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; MOUSE; NONHUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SPOROZOITE;

EID: 0036096045     PISSN: 10150145     EISSN: None     Source Type: Journal    
DOI: 10.1159/000058854     Document Type: Review

References (104)

1. Protective immunity produced by the injection of X-irradiated sporozoites of Plasmodium berghei
2. Antibodies against Plasmodium falciparum vaccine candidates in infants in an area of intense and perennial transmission: Relationships with clinical malaria and with entomological inoculation rates
3. Anti-merozoite surface protein-1 19-kDa IgG in mother-infant pairs naturally exposed to Plasmodium falciparum: Subclass analysis with age, exposure to asexual parasitemia, and protection against malaria. V. The Asembo Bay Cohort Project
4. Transmission-blocking vaccines: Uses and current status of development
5. In vivo induction of the nitric oxide pathway in hepatocytes after injection with irradiated malaria sporozoites, malaria blood parasites or adjuvants
6. Pre-erythrocytic-stage immune effector mechanisms in Plasmodium spp. infections
7. Merozoite surface protein-3: A malaria protein inducing antibodies that promote Plasmodium falciparum killing by cooperation with blood monocytes
8. Cytophilic immunoglobulin responses to Plasmodium falciparum glutamate-rich protein are correlated with protection against clinical malaria in Dielmo, Senegal
9. Pattern of immunoglobulin isotype response to Plasmodium falciparum blood-stage antigens in individuals living in a holoendemic area of Senegal (Dielmo, west Africa)
10. Nitric oxide, malaria, and anemia: Inverse relationship between nitric oxide production and hemoglobin concentration in asymptomatic, malaria-exposed children
11. Nitric oxide in Tanzanian children with malaria: Inverse relationship between malaria severity and nitric oxide production/nitric oxide synthase type 2 expression
12. Blood mononuclear cell nitric oxide production and plasma cytokine levels in healthy Gabonese children with prior mild or severe malaria
13. Interleukin-12-dependent mechanisms in the clearance of blood-stage murine malaria parasite Plasmodium berghei XAT, an attenuated variant of P. berghei NK65
14. The course of Plasmodium chabaudi chabaudi infections in interferon-gamma receptor deficient mice
15. Parasite killing in murine malaria does not require nitric oxide production
16. Nitric oxide expression in the spleen, but not in the liver, correlates with resistance to blood-stage malaria in mice
17. Nitric oxide is neither necessary nor sufficient for resolution of Plasmodium chabaudi malaria in mice
18. Gamma interferon production is critical for protective immunity to infection with blood-stage Plasmodium berghei XAT but neither NO production nor NK cell activation is critical
19. Immune effector mechanisms in malaria
20. Safety, Immunogenicity, and efficacy of Plasmodium falciparum repeatless circumsporozoite protein vaccine encapsulated in liposomes
21. Liposomes containing lipid A: A potent nontoxic adjuvant for a human malaria sporozoite vaccine
22. Immunomodulation by ISCOMs, immune stimulating complexes
23. Liposomal malaria vaccine in humans: A safe and potent adjuvant strategy
24. Liposomes, muramyl dipeptide derivatives, and nontoxic lipid A derivatives as adjuvants for human malaria vaccines
25. Liposomes containing lipid A serve as an adjuvant for induction of antibody and cytotoxic T-cell responses against RTS, S malaria antigen
26. Attenuated vaccinia virus-circumsporozoite protein recombinants confer protection against rodent malaria
27. Phase I/IIa safety, immunogenicity, and efficacy trial of NYVAC-Pf7, a pox-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria
28. NYVAC-Pf7: A poxvirus-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria
29. Monopalmitic acid-peptide conjugates induce cytotoxic T cell responses against malarial epitopes: Importance of spacer amino acids
30. Immunization of owl monkeys with the ring-infected erythrocyte surface antigen of Plasmodium falciparum
31. Role of macrophages in experimental malaria: VI. Effect of Freund's complete adjuvant in Plasmodium berghei infected mice
32. Efficacy of vaccines containing rhoptry-associated proteins RAP1 and RAP2 of Plasmodium falciparum in Saimiri boliviensis monkeys
33. MF59 adjuvant enhances the antibody response to recombinant hepatitis B surface antigen vaccine in primates
34. MF59 adjuvant enhances antibody responses of infant baboons immunized with Haemophilus influenzae type b and Neisseria meningitidis group C oligosaccharide-CRM197 conjugate vaccine
35. Phase I trial of two recombinant vaccines containing the 19kd carboxy terminal fragment of Plasmodium falciparum merozoite surface protein 1 (msp-1(19)) and T helper epitopes of tetanus toxoid
36. Field trials of an asexual blood stage malaria vaccine: Studies of the synthetic peptide polymer SPf66 in Thailand and the analytic plan for a phase IIb efficacy study
37. Phase 1 safety and immunogenicity testing of clinical lots of the synthetic Plasmodium falciparum vaccine SPf66 produced under good manufacturing procedure conditions in the United States
38. Safety, immunogenicity, and efficacy of a recombinantly produced Plasmodium falciparum circumsporozoite protein-hepatitis B surface antigen subunit vaccine
39. Safety, immunogenicity, and pilot efficacy of Plasmodium falciparum sporzoite and asexual blood-stage combination vaccine in Swiss adults
40. An efficacy trial of a malaria vaccine in Gambian infants and comparison with insecticide-treated bednets
41. Randomised double-blind placebo-controlled trial of SPf66 malaria vaccine in children in northwestern Thailand
42. Evaluation of the SPf66 vaccine for malaria control when delivered through the EPI scheme in Tanzania
43. Separation and characterization of saponins with adjuvant activity from Quillaja saponaria Molina cortex
44. Impact of the saponin adjuvant QS-21 and aluminium hydroxide on the immunogenicity of recombinant OspA and OspB of Borrelia burgdorferi
45. Formulation of the purified fusion protein of respiratory syncytial virus with the saponin QS-21 induces protective immune responses in Balb/c mice that are similar to those generated by experimental infection
46. Structure/function studies on QS-21, a unique immunological adjuvant from Quillaja saponaria
47. QS-21: A water-soluble triterpene glycoside adjuvant
48. Phase 1 trial of immunological adjuvant QS-21 with a GM2 ganglioside-keyhole limpet haemocyanin conjugate vaccine in patients with malignant melanoma
49. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria
50. Potent induction of focused Th1-type cellular and humoral immune responses by RTS,S/SBAS2, a recombinant Plasmodium falciparum malaria vaccine
51. Long-term efficacy and immune responses following immunization with the RTS,S malaria vaccine
52. Efficacy of recombinant circumsporozoite protein vaccine regimens against experimental Plasmodium falciparum malaria
53. A phase I safety and immunogenicity trial with the candidate malaria vaccine RTS,S/SBAS2 in semi-immune adults in The Gambia
54. Preclinical evaluation of a synthetic Plasmodium falciparum MAP malaria vaccine in Aotus monkeys and mice
55. Synthetic malaria peptide vaccine elicits high levels of antibodies in vaccinees of defined HLA genotypes
56. High-level expression of Plasmodium vivax apical membrane antigen 1 (AMA-1) in Pichia pastoris: Strong immunogenicity in Macaca mulatta immunized with P. vivax AMA-1 and adjuvant SBAS2
57. Immunization against the murine malaria parasite Plasmodium yoelii using a recombinant protein with adjuvants developed for clinical use
58. Selection of an adjuvant for vaccination with the malaria antigen, MSA-2
59. Phase I trial in humans of an oil-based adjuvant SEPPIC MONTANIDE ISA 720
60. The multi-epitope polypeptide approach in HIV-1 vaccine development
61. Synthetic oligodeoxynucleotides containing CpG motifs enhance immunogenicity of a peptide malaria vaccine in Aotus monkeys
62. High immunogenicity in champanzees of peptides and lipopeptides derived from four new Plasmodium falciparum pre-erythrocytic molecules
63. Protective immunity induced in squirrel monkeys with recombinant apical membrane antigen-1 of Plasmodium fragile
64. Human phase I vaccine trials of 3 recombinant asexual stage malaria antigens with Montanide ISA720 adjuvant
65. Effect of vaccination with 3 recombinant asexual-stage malaria antigens on initial growth rates of Plasmodium falciparum in non-immune volunteers
66. Safety and immunogenicity of a three-component blood-stage malaria vaccine in adults living in an endemic area of Papua New Guinea
67. Copolymer adjuvants in malaria vaccine development
68. Mechanisms of action of nonionic block copolymer adjuvants
69. Effects of a beta-human chorionic gonadotropin subunit immunogen administered in aqueous solution with a novel block copolymer adjuvant in patients with advanced cancer
70. Prolonged expression of IFN gamma induced by protective blood-stage immunization against Plasmodium yoelii malaria
71. Influence of adjuvants on murine immune responses against the C-terminal 19 kDa fragment of Plasmodium vivax merozoite surface protein-1 (MSP-1)
72. Induction of protective antibodies in Saimiri monkeys by immunization with a multiple antigen construct (MAC) containing the Plasmodium vivax circumsporozoite protein repeat region and a universal T helper epitope of tetanus toxin
73. Protective immunity induced in squirrel monkeys with a multiple antigen construct against the circumsporozoite protein of Plasmodium vivax
74. Partial protection against Plasmodium vivax blood-stage infection in Saimiri monkeys by immunization with a recombinant C-terminal fragment of merozoite surface protein 1 in block copolymer adjuvant
75. Testing the efficacy of a recombinant merozoite surface protein (MSP-1 (19) of Plasmodium vivax in Saimiri boliviensis monkeys
76. Advances in vaccine adjuvants
77. Lipopolysaccharide, lipid A, and liposomes containing lipid A as immunologic adjuvants
78. Bacterial cell wall products as adjuvants: Early interferon gamma as marker for adjuvants that enhance protective immunity
79. Monophosphyoryl lipid A as an adjuvant: Past experiences and new direction
80. Murine IgG subclass antibodies to antigens incorporated in liposomes containing lipid A
81. Use of adjuvant containing mycobacterial cell-wall skeleton, monophosphoryl lipid A, and squalane in malaria circumsporozoite protein vaccine
82. Safety, immunogenicity, and efficacy of a malaria sporozoite vaccine administered with monophosphoryl lipid A, cell wall skeleton of mycobacteria, and squalane as adjuvant
83. The adjvant MF59: A 10-year perspective
84. Dendritic cells internalize vaccine adjuvant after intramuscular injection
85. The adjuvant MF59 increases the immunogenicity and protective efficacy of subunit influenza vaccine in mice
86. A subunit cytomegalovirus vaccine based on recombinant envelope glycoprotein B and a new adjuvant
87. Protective immunity induced in Aotus monkeys by a recombinant SERA protein of Plasmodium falciparum: Adjuvant effects on induction of protective immunity
88. Pilot evaluation of influenza virus vaccine (IVV) combined with adjuvant
89. CpG-containing synthetic oligonucleotides promote B and cytotoxic T cell responses to protein antigen: A new class of vaccine adjuvants
90. Stimulation of in vitro murine lymphocyte proliferation by bacterial DNA
91. CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity
92. Repeated administration of cytosine-phosphorothiolated guanine-containing oligonucleotides together with peptide/protein immunization results in enhanced CTL responses with anti-tumor activity
93. Bacterial DNA and immunostimulatory CpG oligonucleotides trigger maturation and activation of murine dendritic cells
94. CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen
95. Interleukin-12- and gamma interferon-dependent protection against malaria conferred by CpG oligodeoxynucleotide in mice
96. TCR vaccines against T cell lymphoma: QS-21 and IL-12 adjuvants induce a protective CD8+ T cell response
97. Interleukin 12 induction of interferon gamma-dependent protection against malaria
98. Sterile protection of monkeys against malaria after administration of interleukin- 12
99. IL-12-induced protection against blood-stage Plasmodium chabaudi AS requires IFN-gamma and TNF-alpha and occurs via a nitric oxide-dependent mechanism
100. Direct immunization of malaria DNA vaccine into the liver by gene gun protects against lethal challenge of Plasmodium berghei sporozoite
101. Improving protective immunity induced by DNA-based immunization: Priming with antigen and GM-CSF-encoding plasmid DNA and boosting with antigen-expressing recombinant poxvirus
102. A plasmid encoding murine granulocyte-macrophage colony-stimulating factor increases protection conferred by a malaria DNA vaccine
103. Pathways for potentiation of immunogenicity during adjuvant-assisted immunizations with Plasmodium falciparum major merozoite surface protein 1
104. Regulation of antibody specificity to Plasmodium falciparum merozoite surface protein-1 by adjuvant and MHC haplotype